Conservative Advocates With Connections to Big

The current consideration in health care has been targeted on Health and Human Services (HHS) Secretary Robert F. Kennedy’s partnership with Department of Agriculture Secretary Brooke Rollins to gain food selection waivers from the states. 

Thus far, 12 states—Arkansas, Colorado, Florida, Idaho, Indiana, Iowa, Louisiana, Nebraska, Oklahoma, Texas, Utah, and West Virginia—have signed on to this push to take away sweet and sugary sodas from SNAP advantages and the elimination of poisonous dyes and ultra-processed meals from its choices. 

Six new states are becoming a member of the MAHA motion! Yesterday at the Great American Farmers Market, @secrollins and @seckennedy signed food selection state waivers for West Virginia , Florida, Colorado, Louisiana, Oklahoma and Texas to take away unhealthy meals from SNAP.… pic.twitter.com/Q8sAqaDBQP

— Dept. of Agriculture (@USDA) August 5, 2025

READ MORE: Gone in a SNAP: RFK Jr. and MAHA End the Decades Long Candy and Soda Gravy Train

The Tuesday news that HHS Secretary Kennedy canceled 22 mRNA vaccine contracts — a practically $500 million partnership with pharmaceutical corporations- has also been making a splash.

While this is terrific news and good points toward Making America Healthy Again, what is slipping beneath the radar is the less shiny and shiny news of Big Pharma’s affect on drug pricing packages. This won’t only have an effect on Americans’ health, but also fuel and increase taxpayer prices. 

On March 29, Senior Editor Joe Cunningham explained the significance of the 340B Drug Pricing Program and reported on Big Pharma’s push to prohibit and even remove this crucial software for rural hospitals to handle their distinctive health care issues.

Enacted in 1992, the 340B program requires pharmaceutical corporations to present discounted medicines to qualifying hospitals and clinics. It’s not funded by taxpayers—drugmakers foot the invoice. And for many rural hospitals across the nation, those reductions are the distinction between staying open or closing their doorways.

Without the 340B program, smaller healthcare suppliers—many already working on razor-thin budgets—wouldn’t have the ability to afford life-saving medicines for their sufferers. And if those hospitals go under, households in the rural half of the nation could be left with few, if any, local choices. It’s not just about inconvenience. In emergency conditions, journey delays can imply the distinction between life and death.

READ MORE: Trump Stands Firm Against Big Pharma, Preserves Lifeline for Rural Hospitals

The Next Threat to Rural Healthcare Isn’t the Big Beautiful Bill

Since the passage of the One Big Beautiful Law (OBBL), watchdog organizations have elevated their calls for for lawmakers to rein in the 340B Drug Pricing Program. 

An April Senate report by Sen. Bill Cassidy (R-LA), documented this system’s abuses by hospitals. His report has been used far and extensive to beat that drum against this system. The Council for Citizens Against Government Waste (CCAGW), a coalition of conservative and constitutional grassroots teams, has also joined this refrain. In a July 16 letter to House Speaker Mike Johnson (R-LA) and Senate Majority Leader John Thune (R-SD), CCAGW deemed 340B reform a crucial step in opposing “Waste, Fraud, and Abuse in Healthcare Industry.” 

Hospitals obtain roughly 37% of all Medicare spending, and 32% of all Medicaid spending–a whole of around $650 billion yearly. Government money creates both dependence and rent searching for habits, but it’s also a conduit for waste, fraud, and abuse. The market distorting actions from these large non-profit hospitals are the motive force of many of the worst issues with our nation’s healthcare.

But a July 29 exclusive by the Washington Examiner has uncovered ties between some of the signatories of this letter and Big Pharma.

Nine of the teams that signed the letter have obtained funding from Pharmaceutical Research and Manufacturers of America, better recognized as PhRMA, the first commerce group representing the pharmaceutical industry. The 340B program forces drug producers to promote their merchandise at decrease costs to sure rural healthcare suppliers, cutting into revenue margins.

Many of the organizations signing the letter have pulled in six-figure sums from PhRMA. 

The Center for a Free Economy, for occasion, reeled in over $500,000 in contributions from the commerce affiliation between 2022 and 2023, about a third of its whole income during the latter yr. Consumer Action for a Strong Economy, meanwhile, introduced in $315,000 in PhRMA contributions between 2021 and 2023.

Other signatories that took vital quantities of money from PhRMA between 2021 and 2023 included the Trade Alliance to Promote Prosperity, which took $175,000, American Commitment, which obtained roughly a quarter million {dollars}, Competitive Enterprise Institute, with $210,000 in PhRMA funding, and the Council for Citizens Against Government Waste, which took in $100,000 between 2019 and 2020.

Of better concern to recipients of the 340B Drug Pricing Program will not be only the disruption to rural health care, but adjustments in its oversight. The Health Resources and Services Administration (HRSA) is presently tasked with this. 

However, experiences have circulated that oversight could also be moved to the Centers for Medicare & Medicaid Services (CMS), which has prioritized cost-cutting measures that align with Big Pharma issues over the hospitals. 

Moving 340B under the CMS will not be just a routine change to the letterhead, specialists said. Instead, it might bode unwell for the safety-net suppliers that benefit from the drug low cost program, which was designed to help susceptible and low-income sufferers access medicines by requiring drugmakers to give reductions on outpatient medication to sure hospitals and clinics that qualify.

Roughly 3,000 hospitals benefit from discounted medication under this system, which accounted for a file $66.3 billion in purchases in 2023, according to authorities data. That’s up more than 50% from $43.9 billion just two years prior.

Critics of 340B say this system has mutated properly past its authentic intent. Drugmakers argue that hospitals are manipulating 340B in order to revenue, while hospitals say drugmakers are trying to keep away from shelling out reductions they’re owed to shield their backside strains. That’s as 340B financial savings will be steep — usually 20% to 50% off the record price of a drug.

Follow the #340B {dollars}: After changing into #340B coated entities, disproportionate share hospitals (DSH) increase investments…in shares, bonds, and other financial devices! Meanwhile, investments in uncompensated care have been flat/down. 👇

The 340B program desperately wants to… pic.twitter.com/fB0fgs4Maf

— Adam J. Fein (@DrugChannels) July 31, 2025

Follow the #340B {dollars}: After changing into #340B coated entities, disproportionate share hospitals (DSH) increase investments…in shares, bonds, and other financial devices! Meanwhile, investments in uncompensated care have been flat/down.  

The 340B program desperately wants to be modernized so that it advantages the real safety-net providers of healthcare suppliers, while appropriately supporting low-income and uninsured sufferers.  

Source: @MagnoliaAccess

 https://drugch.nl/44TT3H4

Community health facilities (CHCs) that can be disproportionately affected by these adjustments are declaring the abuses of this system, which only serve to rob the communities that most need it. They are also pushing back and sounding the alarm.

An important software CHCs use to develop access is the 340B Drug Pricing Program, which requires drug producers to offer reductions to safety-net suppliers. The program was designed to scale back financial limitations for sufferers, serving to them afford life-saving medicines and permitting suppliers to reinvest in expanded care.

But over time, that mission has been compromised. Large hospital systems, not certain by the same degree of accountability, have taken benefit of this system’s lack of transparency. Well-funded hospitals should purchase medication at steep reductions, invoice sufferers or insurers full price, and pocket the distinction. Meanwhile, the sufferers this system was created to help, particularly in rural and low-income areas, are being left behind.

Now, with potential cuts to Medicaid looming, the need for reform is even more pressing. Community Health Centers are already stretched skinny. If 340B financial savings continue to be siphoned away from true safety-net suppliers, the implications for susceptible Pennsylvanians might be devastating.

It is clear that more targeted oversight to stop additional fraud, waste, and abuse wants to happen. However, ought to pharmaceutical corporations with a vested curiosity in seeing the 340B Drug Pricing Program restricted or eradicated be so intimately concerned in the method? 

Even tenuous connections from some of the CCAGW orgs to PhRMA raise professional issues about Big Pharma’s affect and attain.

In addition to the 340B program, the letter touched on other points, including Medicaid reform and tax coverage.

The pharmaceutical industry has a sturdy affect community, paying for lobbying campaigns, media affect operations, and advocacy operations across the nation.

It boils down to the motion of the executive arm, and presently, HRSA seems to be keen to take a look at out the rebate program that the major drug suppliers have been clamoring for. On July 31, HRSA announced a “voluntary” 340B Rebate Model Pilot Program.

Today, the Health Resources and Services Administration (HRSA) announced the provision of a voluntary 340B Rebate Model Pilot Program for medication on the CMS Medicare Drug Price Negotiation Selected Drug List for yr 2026 from qualifying producers assembly particular standards. 

HRSA is introducing this pilot program to take a look at the rebate model on these medication in a methodical and considerate strategy to guarantee a truthful and clear 340B rebate model course of.  HRSA is implementing this pilot to better perceive the deserves and shortcomings of the rebate model from the attitude of affected stakeholders, and to help form any future 340B rebate fashions that align with the 340B statute and the Administration’s objectives. 

“The 340B Program provides vital healthcare access for high-need communities by allowing health care providers – also known as covered entities – to purchase medications at reduced prices,” said HRSA Administrator Tom Engels. “Today’s announcement of the availability of a Rebate Model Pilot Program addresses concerns we have received from both covered entities and manufacturers, while creating a measured approach to the process of approving manufacturer rebate models under the 340B Program. We look forward to receiving comments and working with everyone to ensure that the program operates with accountability, transparency and adherence to the 340B statute, allowing covered entities to stretch scarce resources as far as possible.”

The OBBL cuts to Medicaid are supposed to fight fraud and shore up the protection web for the residents for whom it was supposed, while the $50 billion Rural Health Transformation Program will bolster reinvestment in rural hospitals and CHCs. 

The hope is that these measures will strengthen the dedication to precise affected person care while driving financial savings for the taxpayer. Both of those working in tandem can help blunt Big Pharma’s insidious affect across the health care panorama. 

Editor’s Note: Help us continue to report the reality about corrupt politicians like Sen. Bill Cassidy. 

Join RedState VIP and use promo code FIGHT to get 60% off your membership.